How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy? - MarketWatch
Sentiment Mix
Geography
Expert Signals
Politics - Google News US Headlines
source • 1 mention
AI-Generated Claims
Generated from linked receipts; click sources for full context.
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs.
Supported by 1 story
Lilly: Q2's cardiometabolic grudge match Endpoints NewsObesity battle heats up again as Novo claws way back into race with Lilly
Supported by 1 story
Related Events
Europe encourages its neighbours to practise migration blackmail - The Economist
Uncategorized • 8/6/2026
Cathay Pacific's profit soars 71% despite Iran war driving up fuel costs - Japan Today
Uncategorized • 8/6/2026
Canada-U.S. trade down almost $2B in two years - CTV News
Uncategorized • 8/6/2026
'This was not an exceptional result': Why AMD stock tanked 5% after earnings - Yahoo Finance
Hardware • 8/6/2026
Tariffs led to price changes for majority of Canadian businesses: KPMG poll
Uncategorized • 8/6/2026